Bevacizumab in ovarian cancer: Unanswered questions

Drugs

Volumn 72, Issue 7, 2012, Pages 931-936

  Muggia, Franco ^a  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Angiogenesis inhibitors; Bevacizumab; Capecitabine; Carboplatin; Docetaxel; Doxorubicin liposomal; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer.

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; GALACTOSE OLIGOSACCHARIDE; GEMCITABINE; PACLITAXEL; PLACEBO;

ARTERIAL THROMBOEMBOLISM; BLEEDING; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; COST BENEFIT ANALYSIS; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HAZARD RATIO; HUMAN; HYPERTENSION; NOTE; OVARY CARCINOMA; PHASE 2 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; PROTEINURIA; RISK; WOUND DEHISCENCE;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FALLOPIAN TUBE NEOPLASMS; FEMALE; HUMANS; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS;

EID: 84860722659     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11633510-000000000-00000     Document Type: Note

References (19)

1. Muggia F, Safra T, Dubeau L. BRCA genes: lessons learned from experimental and clinical cancer. Ann Oncol 2011; 22 Suppl. 1: 7-10
2. National Cancer Institute at the National Institutes of Health. PDQ ovarian cancer [online]. Available from URL: http://www.cancer.gov [Accessed 2012 Mar 1]
3. Burger RA, Sill MW, Monk BJ, et al. Phase II study of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group study. J Clin Oncol 2007; 25: 5165-71
4. Cannistra SA, Matulonis UA, Penson RT, et al. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer [published erratum appears in J Clin Oncol 2008 Apr 1; 26 (10): 1773]. J Clin Oncol 2007 Nov 20; 25 (33): 5180-6
5. Dhillon S. Bevacizumab combination therapy: for the first-line treatment of advance epithelial ovarian, fallopian tube or primary peritoneal cancer. Drugs 2012; 72 (7): 917-30
6. Burger RA, Brady MF, Bookman MA, et al., for the Gynecologic Oncology Group. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Eng J Med 2011; 365 (26): 2473-83
7. Perren TJ, Swart AM, Pfisterer J, et al., for the ICON7 investigators. A phase 3 trial of bevacizumab in ovarian cancer. N Eng J Med 2011 Dec 29; 365 (26): 2484-96
8. No authors listed. Ovarian cancer: breaking the silence. Lancet Oncol 2012 Feb; 13 (2): 111
9. Aghajanian C, Finkler NJ, Rutherford T, et al. OCEANS: a randomized, double-blinded, placebo-controlled phase III trial of chemotherapy with or without bevacizumab (BEV) in patients with platinum-sensitive recurrent epithelial ovarian (EOC), primary peritoneal (PPC), or fallopian tube cancer (FTC) [abstract no. LBA5007]. J Clin Oncol 2011; 29
10. Kristensen G. Result of interim analysis of overall survival in the GCIG ICON7 phase III randomized trial of bevacizumab in women with newly diagnosed ovarian cancer [abstract no. LBA2006. J Clin Oncol 2011; 29: 781s
11. Reck M, von Pawel J, Zatloukal P, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-smallcell lung cancer: AVail. J Clin Oncol 2009; 27: 1227-34
12. Ocañ a A, Amir E, Vera F, et al. Addition of bevacizumab to chemotherapy for treatment of solid tumors: similar results but different conclusions. J Clin Oncol 2011; 29: 254-6
13. Nick A, Stone R, Soliman P, et al. Pressure to respond: hypertension predicts clinical benefit from bevacizumab in recurrent ovarian cancer [abstract no. 84]. Gynec Oncol 2011; 120: S37
14. Stone RL, Sood AK, Coleman RL. Collateral damage: toxic effects of targeted antiangiogenic therapies in ovarian cancer. Lancet Oncol 2010; 11: 465-75
15. Cannistra SA. Challenges and pitfalls of combining targeted agents in phase I studies. J Clin Oncol 2008; 26: 3665-7
16. Verschraegen C, Czok S, Muller CY, et al. Phase II study of bevacizumab with pegylated liposomal doxorubicin for patients with platinum and taxane resistant ovarian cancer. Ann Oncol. In press
17. Allegra CJ, Yothers G, O'Connell MJ, et al. Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08. J Clin Oncol 2010; 29: 11-6
18. Jain RK, Duda DG, Willett CG, et al. Biomarkers of response and resistance to antiangiogenic therapy. Nat Rev Clin Oncol 2009; 6: 327-38
19. Shah DK, Shin BS, Veith J, et al. Use of an anti-vascular endothelial growth factor antibody in a pharmacokinetic strategy to increase the efficacy of intraperitoneal chemotherapy. J Pharmacol Exp Ther May 2009; 329: 580-91